SecBot SecBot
DEFA14A ·Filed Apr 29, 2026

LIVN

LivaNova PLC
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago SEC0001104659-26-050942
Proxy solicitation materials
Actionable Insight • Neutral

This filing is a routine proxy notice with no material financial updates or activist activity. The AGM is scheduled for June 10, 2026; monitor for any dissident filings or guidance releases ahead of the meeting.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.92
T+0 close · Apr 29, 2026 · via day close
Latest settled
+32.71%
T+60 · $78.19
Vs SPY
+28.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $58.92entry
  2. T+1 · 7mo ago +2.00%α +0.98% · $60.10
  3. T+5 · 7mo ago +12.46%α +9.35% · $66.26
  4. T+20 · 6mo ago +23.96%α +17.92% · $73.04
  5. T+60 · 4mo ago +32.71%α +28.59% · $78.19

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

LivaNova filed a definitive additional proxy soliciting material (DEFA14A) providing notice of its 2026 Annual General Meeting to be held on June 10, 2026. Shareholders will vote on the election of 11 directors, advisory say-on-pay, auditor ratification, share allotment authority, and share repurchase authorization. The board recommends voting FOR all proposals. This is a routine filing with no material financial information or activist activity.

Key Financial Metrics

Vote
director election
Meeting
2026-06-10

Key Facts

  • Annual General Meeting scheduled for June 10, 2026 at 3:00 pm BST / 10:00 am ET
  • Proposals include election of 11 directors, advisory say-on-pay, auditor ratification, share allotment authority up to £10,985,296, and authorization for share repurchases of up to 10% of outstanding shares
  • Board of Directors recommends voting FOR all proposals

Financial Impact

Not specified

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
76% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-050942
Document: 0001104659-26-050942-index-headers.html0001104659-26-050942
Document: 0001104659-26-050942-index.html0001104659-26-050942
Document: 0001104659-26-050942.txt0001104659-26-050942

Track record

10 reports on LIVN

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.95% at T+60 after the May 6, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $94.19 Now $92.44 −1.86% settles Feb 2
  5. Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
  6. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
  7. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
  8. May 6, 202627w ago 8-K Bullish 8/10 Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
  9. Apr 29, 202628w ago DEFA14A Neutral 2/10 Viewing Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
  10. Feb 25, 202637w ago 8-K Bullish 7/10 Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (10h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026